Disfibrinogenemiya and Hidden Hemolysis - Indicators of Hemorrhagic Syndrome in Erysipelas

Elena. G. Fokina

Authors

Elena. G. Fokina

Keywords:

facial erysipelas, lower-limb erysipelas, hidden hemolysis, DIC-like syndrome, erythrocyte aggregation, platelet aggregation, fibrinogen, D-dimer, pro

Abstract

Abstract not found

Downloads

How to Cite

Disfibrinogenemiya and Hidden Hemolysis - Indicators of Hemorrhagic Syndrome in Erysipelas. (2016). Global Journal of Medical Research, 16(C1), 1-11. https://medicalresearchjournal.org/index.php/GJMR/article/view/1105

Download Citation

References

E Fokina, I Rosly, S Potekaeva (2014) Laboratory evaluation of erysipelatous imflammation // Epidemiologia i infekcionnye bolezni. Aktualnye voprosy (Epidemiology and infectious diseases. 1, 28-32.

François Denis, Marie-Cécile Ploy, Christian Martin, Édouard Bingen, Roland Quentin (2001) Introduction. 128, xv-xvi.

E Pchelenok, S Kosyakov, A Vinnikov (2015) Necrotizing (malignant) external otitis: a modern review of diagnosis and management. 22(3), 70-73.

A Frolov Etiopathgenetic particularities of the development of necrotic form of erysipelas, its prediction and principles of complex therapy// Synopsis of PhD thesis.

M Mitrofanova, Yu (2010) Disturbances of hemostasis and vascular endothelial function in patients with erysipelas// Synopsis of PhD thesis.

Sheremetiev Yu, G Makin, F Suslov, Yu (1995) A method for the registration of the changes of surface erythrocyte charge (lanthanum chloride)// Federal Service for Intellectual Property. 2027188.

Despo Papachristodoulou, Alison Snape, William Elliott, Daphne Elliott (2014) Biochemistry and Molecular Biology. 592.

E Fokina (2014) Some particularities of primary erysipelas under present-day conditions.// Terapevtichesky arkhiv. 11, 70-77.

F Castellino, V Ploplis (2009) The protein C pathway and pathologic processes. 7(1), 140-145.

B Dahlback (1997) Resistance to activated protein C as risk factor for thrombosis: molecular mechanism, laboratory investigation and clinical managements. 34(3), 217-234.

C Esmon (2001) Role of coagulation inhibitors in inflammation. 86, 51-56.

L Ratnikova, T Dubovikova (2012) Evaluation of the state of vascular platelet hemostasis in patients with hemorrhagic forms of erysipelas// Zhurnal infectologii. 4(1), 53-57.

L Bockeria, L Klimovich, A Potekhina (2004) Mechanisms of coagulation inhibitors involvement into the development of inflammatory reaction and perspective trends of anticoagulation therapy// Klinicheskaya fisiologia krovoobraschenia (Clinical physiology of the circulation) Moscow. 1, 46-55.

Gordon Bernard, Jean-Louis Vincent, Pierre-Francois Laterre, Steven Larosa, Jean-Francois Dhainaut, Angel Lopez-Rodriguez, Jay Steingrub, Gary Garber, Jeffrey Helterbrand, E Ely, Charles Fisher (2001) Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. 344(10), 699-709.

S Coughlin (2001) Protease-activated receptors in vascular biology. 86, 298-307.

C Esmon, F Taylor (1991) Inflammation and coagulation: Linked processes potential regulated through a common pathway mediated by protein C. 66, 160-165.

D Chen, A Dorling (2009) Critical roles for thrombin in acute and chronic inflammation. 7(1), 122-126.

Prasanna Sridharan, Ronald Chamberlain (2013) The Efficacy of Procalcitonin as a Biomarker in the Management of Sepsis: Slaying Dragons or Tilting at Windmills?. 14(6), 489-511.

B Kile (2009) The role of the intrinsic apoptosis pathway in platelet life and death. 7(1), 214-217.